Hong Kong Building Stock News

SEHK:1398
SEHK:1398Banks

A Look At ICBC (SEHK:1398) Valuation After Its RMB 60,000 Million Tier 2 Capital Notes Issuance

Industrial and Commercial Bank of China (SEHK:1398) has just completed a RMB 60,000 million Tier 2 capital notes issuance in the National Interbank Bond Market, a financing step aimed at strengthening its tier 2 capital position. See our latest analysis for Industrial and Commercial Bank of China. The HK$6.83 share price has a 1-day share price return of 1.64% and a 7-day share price return of 2.86%. The 1-year total shareholder return of 26.07% and 5-year total shareholder return of 104.62%...
SEHK:2460
SEHK:2460Beverage

China Resources Beverage (Holdings) (SEHK:2460) Valuation After Approval Of 2025 Special And Final Dividends

China Resources Beverage (Holdings) (SEHK:2460) has drawn investor attention after shareholders approved both a final dividend and a special dividend for 2025 at the company’s latest annual general meeting. See our latest analysis for China Resources Beverage (Holdings). Despite the dividend approvals, the stock’s recent momentum has been weak, with a 30 day share price return of down 6.24% and a year to date share price return of down 19.94%, while the 1 year total shareholder return is down...
SEHK:3866
SEHK:3866Banks

Assessing Bank of Qingdao (SEHK:3866) Valuation After AGM Dividend Approval and Tier Two Bond Redemption

Bank of Qingdao (SEHK:3866) has put shareholder returns and capital structure in focus after its 2025 AGM, approving a cash dividend and confirming the full early redemption of its RMB 2b tier two capital bonds. See our latest analysis for Bank of Qingdao. Recent price action has been mixed, with a 1-day share price return of 0.69% at HK$4.35 following the AGM, set against a 30-day share price decline of 9.38%. However, the year to date share price return of 13.87% and a 3-year total...
SEHK:268
SEHK:268Software

Assessing Kingdee International Software Group’s Valuation After Governance Changes And Return To Net Income

Governance changes and recent financial recovery take center stage Kingdee International Software Group (SEHK:268) has drawn fresh attention after shareholders approved new amended and restated Articles of Association, together with the company’s recent shift from a net loss to net income in 2025. See our latest analysis for Kingdee International Software Group. Despite the recent governance changes and return to profitability, the share price has been under pressure, with the 1-year total...
SEHK:3388
SEHK:3388Tech

Assessing Shenzhen Creality 3D Technology (SEHK:3388) Valuation After Recent Share Price Weakness

Recent share price move puts Shenzhen Creality 3D Technology in focus A sharp one day move has put Shenzhen Creality 3D Technology (SEHK:3388) on investors’ radar, with the stock falling about 9% in the latest session and roughly 8% year to date. With a market value of about HK$9.8b and reported revenue of CN¥3,127.04m against a net loss of CN¥182.561m, the company sits at an interesting point for investors assessing growth potential versus current profitability. See our latest analysis for...
SEHK:2269
SEHK:2269Life Sciences

Assessing WuXi Biologics (SEHK:2269) Valuation After Its Recent Share Price Momentum Shift

Recent share performance and company snapshot WuXi Biologics (Cayman) (SEHK:2269) has seen mixed share performance recently, with the stock edging up about 1% over the past day but declining around 10% over the past 3 months. The company runs an end to end biologics contract research, development, and manufacturing business, serving clients across North America, Europe, the People’s Republic of China, and other regions. It reported revenue of CN¥21,790.018 million and net income of...
SEHK:6990
SEHK:6990Biotechs

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Is Down 14.8% After ASCO NSCLC Data Spotlight - Has The Bull Case Changed?

At the 2026 ASCO Annual Meeting, Sichuan Kelun-Biotech Biopharmaceutical reported past Phase III and Phase II data in NSCLC, including sacituzumab tirumotecan plus pembrolizumab showing longer progression-free survival than pembrolizumab alone and lunbotinib fumarate delivering high response rates in RET fusion-positive disease, alongside encouraging first-in-human results for its B7-H3 ADC SKB500. The inclusion of sacituzumab tirumotecan data in The Lancet and the acceptance of lunbotinib’s...
SEHK:1952
SEHK:1952Biotechs

Everest Medicines (SEHK:1952) Valuation Check After Recent Share Price Weakness

Everest Medicines Stock Moves After Recent Performance Metrics Everest Medicines (SEHK:1952) has drawn fresh attention as investors review recent share performance and financial metrics, with the stock down 1% over the past day and 4.6% over the past week. See our latest analysis for Everest Medicines. That 1 day and 7 day share price weakness comes on top of a 30 day share price return of down 14.8% and a year to date decline of 24.1%. The 3 year total shareholder return of about 1.7x the...
SEHK:1211
SEHK:1211Auto

BYD Takes On Driver Risk While Advancing Toward Solid State Batteries

BYD (SEHK:1211) has said it will assume liability for its advanced driver-assistance system, signaling a higher level of accountability for its technology. The company has also outlined plans to introduce solid-state batteries by 2027, targeting the next generation of electric vehicle battery performance. BYD shares last closed at HK$89.7, with the stock down 32.5% over the past year and still positive over 3 and 5 years, up 10.5% and 29.5% respectively. Against that backdrop, the company...